Dividend payouts are a vital part of the return that investors get from owning stocks over time. Whether you're after large-cap cash cows or small-cap growth stocks, dividends can be a pointer to well financed, well managed companies -...
ABBV — Abbvie Share Price
0.000.00%
Last Trade - 00:00HealthcareConservativeLarge CapSuper Stock
- $211.46bn
- $285.02bn
- $53.73bn
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 8.9 | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | 4.48% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 25,638 | 28,216 | 32,753 | 33,266 | 45,804 | 56,367.21 | 59,840.85 | 14.91% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +13.59 | +4.54 | +59.17 | -8.27 | -36.44 | +245.65 | +9.97 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
12345678910
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Latest News & Insights for ABBV
Dividend payouts are a vital part of the return that investors get from owning stocks over time. Given the volatility in financial markets caused by Covid however, it is becoming difficult to assess whether dividend forecasts are still...
Covid-19 has shaken world markets. One question likely to be on the minds of a lot of investors right now is how economic uncertainty caused by the pandemic will continue to affect large cap shares, such as the share price of Abbvie In...
Quality and value are two of the most important drivers of stock market returns - yet many investors fail to take them seriously. At a time of deep economic uncertainty, using these two powerful factors to find stocks could help you na...
The Abbvie Inc (NYQ:ABBV) share price is currently trading at 91.04. But to try and predict what the price will look like in the next 12 months and beyond, it's worth knowing its strengths and potential weaknesses. The good news for sh...
Profile Summary
AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. AbbVie offers its products in various therapeutic categories, including Immunology products, which include Humira, Skyrizi and Rinvoq; Oncology products consists of Imbruvica and Venclexta; Aesthetics products include Botox Cosmetic, Juvederm Collection and other aesthetics; Neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; Eye care products consists of Lumigan, Alphagan and Restasis ; Women's health products incudes Lo Loestrin, Orilissa and other women's health; and Other key products, which includes Mavyret, Creon, Lupron, Linzess and Synthroid. The Company's products are sold worldwide directly to wholesalers, distributors, government agencies, health care facilities and independent retailers from AbbVie-owned distribution centers and public warehouses.
Directors
- Richard Gonzalez
- Michael Severino PRE
- Laura Schumacher VMG (57)
- Robert Michael CFO
- Timothy Richmond CHO
- Henry Gosebruch (48)
- Azita Saleki - Gerhardt EVP (57)
- Thomas Hudson (59)
- Elaine Sorg (54)
- Jeffrey Stewart (52)
- Carrie Strom (43)
- Brian Durkin (60)
- Glenn Tilton (72)
- Robert Alpern (70)
- Roxanne Austin (60)
- William Burnside (69)
- Thomas Freyman (66)
- Brett Hart (51)
- Edward Liddy (75)
- Melody Meyer (63)
- Edward Rapp (63)
- Rebecca Roberts (68)
- Frederick Waddell (67)
- Last Annual
- December 31st, 2020
- Last Interim
- June 30th, 2021
- Incorporated
- April 10th, 2012
- Public Since
- January 2nd, 2013
- No. of Shareholders
- 47,754
- No. of Employees
- 48,000
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- New York Stock Exchange
- Shares in Issue
- 1,767,175,532
- Address
- 1 N Waukegan Rd, NORTH CHICAGO, 60064-1802
- Web
- https://www.abbvie.com/
- Phone
- +1 8479327900
- Auditors
- Ernst & Young LLP
Latest News for ABBV
Upcoming events for ABBV
Q3 2021 Abbvie Inc Earnings Release
Similar to ABBV
AMNEAL PHARMACEUTICALS CL A ORD
New York Stock Exchange
ARCUS BIOSCIENCES ORD
New York Stock Exchange
BAUSCH HEALTH COMPANIES ORD
New York Stock Exchange
BRISTOL MYERS SQUIBB ORD
New York Stock Exchange
CATALENT ORD
New York Stock Exchange
FAQ
What is the Abbvie share price?
As of Today at 19:54 UTC, shares in Abbvie are trading at $119.66. This share price information is delayed by 15 minutes.
How has the Abbvie share price performed this year?
Shares in Abbvie last closed at $119.66 and the price had moved by +24.19% over the past 365 days. In terms of relative price strength the Abbvie share price has underperformed the S&P500 Index by -5.78% over the past year.
What are the analyst and broker recommendations for Abbvie?
The overall consensus recommendation for Abbvie is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Abbvie dividend yield?
The Abbvie dividend yield is 4.15% based on the trailing twelve month period.
Does Abbvie pay a dividend?
Last year, Abbvie paid a total dividend of $4.96, and it currently has a trailing dividend yield of 4.15%. We do not have any data on when Abbvie is to next pay dividends.
When does Abbvie next pay dividends?
We do not have data on when Abbvie is to next pay dividends. The historic dividend yield on Abbvie shares is currently 4.15%.
How do I buy Abbvie shares?
To buy shares in Abbvie you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Abbvie?
As of the previous close price of $119.66, shares in Abbvie had a market capitalisation of $211.46bn.
Where are Abbvie shares listed?
Here are the trading details for Abbvie:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: ABBV
What kind of share is Abbvie?
Based on an overall assessment of its quality, value and momentum Abbvie is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Abbvie share price forecast for 2021?
The analyst consensus target price for shares in Abbvie is $126.28. That is 5.53% above the last closing price of $119.66.
Analysts covering Abbvie currently have a consensus Earnings Per Share (EPS) forecast of $12.65 for the next financial year.
What is the trend in the Abbvie share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Abbvie. Over the past six months, its share price has underperformed the S&P500 Index by -1.35%.
As of the last closing price of $119.66, shares in Abbvie were trading +9.66% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Abbvie PE Ratio?
The Abbvie PE ratio based on its reported earnings over the past 12 months is 12.83. The shares last closed at $119.66.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Abbvie?
Abbvie's management team is headed by:
- Richard Gonzalez -
- Michael Severino - PRE
- Laura Schumacher - VMG
- Robert Michael - CFO
- Timothy Richmond - CHO
- Henry Gosebruch -
- Azita Saleki - Gerhardt - EVP
- Thomas Hudson -
- Elaine Sorg -
- Jeffrey Stewart -
- Carrie Strom -
- Brian Durkin -
- Glenn Tilton -
- Robert Alpern -
- Roxanne Austin -
- William Burnside -
- Thomas Freyman -
- Brett Hart -
- Edward Liddy -
- Melody Meyer -
- Edward Rapp -
- Rebecca Roberts -
- Frederick Waddell -
Who are the major shareholders of Abbvie?
We do not have data on Abbvie's shareholders